Compare KR & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KR | CRNX |
|---|---|---|
| Founded | 1883 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 4.1B |
| IPO Year | N/A | 2018 |
| Metric | KR | CRNX |
|---|---|---|
| Price | $70.92 | $42.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $72.75 | ★ $75.78 |
| AVG Volume (30 Days) | ★ 7.2M | 1.0M |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $147,225,000,000.00 | $1,535,000.00 |
| Revenue This Year | $3.78 | $499.13 |
| Revenue Next Year | $2.10 | $893.14 |
| P/E Ratio | $60.44 | ★ N/A |
| Revenue Growth | N/A | ★ 47.74 |
| 52 Week Low | $58.60 | $24.10 |
| 52 Week High | $74.90 | $57.99 |
| Indicator | KR | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 68.70 | 36.05 |
| Support Level | $67.44 | $43.94 |
| Resistance Level | $72.24 | $48.58 |
| Average True Range (ATR) | 2.02 | 2.53 |
| MACD | 0.67 | -0.77 |
| Stochastic Oscillator | 75.00 | 5.33 |
Kroger is one of the largest grocery retailers in the United States with about 2,700 stores across a portfolio of more than 20 supermarket banners. The company boasts an ingrained presence in US communities, citing that it is a top-two grocer in most of its major market areas. Over one fourth of Kroger's roughly $110 billion in nonperishable and fresh food sales (about 75% of revenue) stems from its private-label portfolio, of which the company manufactures about 30% of units via its own food production plants. The company also operates fuel stations and pharmacies at 60% and 80% of its locations, respectively.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.